CLINICAL TRIALS PROFILE FOR NALOXEGOL OXALATE

All Clinical Trials for NALOXEGOL OXALATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04219046 ↗	Evaluation of Naloxegol in the Prevention of POI After Cystectomy	Not yet recruiting	Institut Paoli-Calmettes	Phase 2	2021-03-01	Postoperative ileus (POI) is defined as a transient reduction of bowel motility that prevents effective transit of bowel content and tolerance of oral intake following surgical interventions, especially after radical cystectomy. It remains a major factor associated with postoperative morbidity, length of hospital stay and medical costs. In order to optimize perioperative care for patients undergoing radical cystectomy in a context of an ERAS (Enhanced Recovery After Surgery) program, we will evaluate the effectiveness of systemic pharmacologic opioid antagonist treatment.

Clinical Trial Conditions for NALOXEGOL OXALATE

Condition Name

Condition Name for NALOXEGOL OXALATE
Intervention	Trials
Bladder Cancer	1
Cystostomy; Complications	1

Condition MeSH

Condition MeSH for NALOXEGOL OXALATE
Intervention	Trials
Urinary Bladder Neoplasms	1

Clinical Trial Progress for NALOXEGOL OXALATE

Clinical Trial Phase

Clinical Trial Phase for NALOXEGOL OXALATE
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for NALOXEGOL OXALATE
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for NALOXEGOL OXALATE

Sponsor Name

Sponsor Name for NALOXEGOL OXALATE
Sponsor	Trials
Institut Paoli-Calmettes	1

Sponsor Type

Sponsor Type for NALOXEGOL OXALATE
Sponsor	Trials
Other	1